- Home
- SNDR vs IONS Comparison
SNDR vs IONS Comparison
Compare SNDR & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDR
- IONS
- Stock Information
- Founded
- SNDR 1935
- IONS 1989
- Country
- SNDR United States
- IONS United States
- Employees
- SNDR N/A
- IONS N/A
- Industry
- SNDR Trucking Freight/Courier Services
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- SNDR Industrials
- IONS Health Care
- Exchange
- SNDR Nasdaq
- IONS Nasdaq
- Market Cap
- SNDR 5.2B
- IONS 6.0B
- IPO Year
- SNDR 2017
- IONS 1991
- Fundamental
- Price
- SNDR $27.35
- IONS $32.32
- Analyst Decision
- SNDR Buy
- IONS Buy
- Analyst Count
- SNDR 14
- IONS 19
- Target Price
- SNDR $30.77
- IONS $61.24
- AVG Volume (30 Days)
- SNDR 801.7K
- IONS 1.8M
- Earning Date
- SNDR 01-30-2025
- IONS 02-19-2025
- Dividend Yield
- SNDR 1.39%
- IONS N/A
- EPS Growth
- SNDR N/A
- IONS N/A
- EPS
- SNDR 0.66
- IONS N/A
- Revenue
- SNDR $5,290,500,000.00
- IONS $705,138,000.00
- Revenue This Year
- SNDR $14.81
- IONS N/A
- Revenue Next Year
- SNDR $7.21
- IONS $10.08
- P/E Ratio
- SNDR $41.33
- IONS N/A
- Revenue Growth
- SNDR N/A
- IONS N/A
- 52 Week Low
- SNDR $20.50
- IONS $30.23
- 52 Week High
- SNDR $33.90
- IONS $52.34
- Technical
- Relative Strength Index (RSI)
- SNDR 27.06
- IONS 48.36
- Support Level
- SNDR $27.43
- IONS $30.86
- Resistance Level
- SNDR $28.01
- IONS $34.74
- Average True Range (ATR)
- SNDR 0.60
- IONS 1.35
- MACD
- SNDR -0.22
- IONS 0.18
- Stochastic Oscillator
- SNDR 0.83
- IONS 46.34
About SNDR Schneider National Inc.
Schneider National Inc is a provider of surface transportation and logistics solutions in North America. The Company offers truckload, intermodal, and logistics services to a diverse customer base throughout the continental United States, Canada, and Mexico. The company's segments include Truckload; Intermodal; Logistics and other. It generates maximum revenue from the Truckload segment.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.